80,660 Shares in OPKO Health, Inc. (NASDAQ:OPK) Purchased by Virtu Financial LLC

Virtu Financial LLC bought a new stake in shares of OPKO Health, Inc. (NASDAQ:OPK) in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 80,660 shares of the biotechnology company’s stock, valued at approximately $120,000.

Several other institutional investors and hedge funds also recently modified their holdings of OPK. CIBC Asset Management Inc boosted its stake in shares of OPKO Health by 79.1% during the second quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 8,978 shares during the last quarter. FMR LLC lifted its holdings in OPKO Health by 103.6% in the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 11,089 shares in the last quarter. Algert Global LLC acquired a new stake in shares of OPKO Health during the 2nd quarter worth about $44,000. Orion Portfolio Solutions LLC purchased a new stake in shares of OPKO Health during the third quarter worth about $45,000. Finally, Private Advisor Group LLC raised its position in shares of OPKO Health by 242.7% in the third quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 25,000 shares during the last quarter. Hedge funds and other institutional investors own 64.63% of the company’s stock.

Insider Activity

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 100,000 shares of the business’s stock in a transaction dated Thursday, November 14th. The shares were acquired at an average price of $1.62 per share, with a total value of $162,000.00. Following the purchase, the chief executive officer now owns 211,612,405 shares in the company, valued at approximately $342,812,096.10. The trade was a 0.05 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have bought 1,304,255 shares of company stock valued at $2,024,605 in the last three months. Corporate insiders own 47.26% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Piper Sandler restated an “overweight” rating and set a $3.00 target price on shares of OPKO Health in a research report on Tuesday, September 17th. StockNews.com raised OPKO Health from a “sell” rating to a “hold” rating in a research note on Wednesday. Barrington Research reaffirmed an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research note on Friday, November 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a research report on Thursday, September 26th.

OPKO Health Price Performance

OPK stock opened at $1.57 on Friday. The company has a market cap of $1.07 billion, a PE ratio of -8.26 and a beta of 1.62. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The stock has a 50-day moving average price of $1.54 and a two-hundred day moving average price of $1.48. OPKO Health, Inc. has a 12-month low of $0.85 and a 12-month high of $1.76.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.